NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,199.70
- Market cap
- ₹1,20,718 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 41.3×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Zydus Lifesciences Other Announcement
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Q2 FY27 Results: Net Profit ₹925.5 Cr, Down 26.6% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹7,910 Cr (+29.2% YoY) and net profit of ₹925.5 Cr (-26.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹925.5 Cr · -26.6% YoY
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Other results update announcements
All →Steel Exchange India Results Update
Steel Exchange India Ltd reported a nine-fold surge in Q2 FY27 PAT to ₹18 Crore. Revenue rose 46% to ₹343 Crore alongside a ₹102 Crore debt reduction.
- quarterly production
- 69617.42 MT
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
SJS Enterprises Results Update
S.J.S. Enterprises reported record quarterly revenue of Rs. 282.73 Crore, up 16.9% YoY. Net profit for Q2FY27 rose 34.8% YoY to Rs. 58.33 Crore.
- Value
- ₹282.7 Cr
Meghmani Organics Results Update
MOL reported Q2 FY27 revenue of ₹658.2 crore, up 18% YoY, with net profit of ₹45.3 crore. EBITDA margin eased to 10.8% on elevated input costs.
GPT Infraprojects Results Update
GPT Infraprojects reported Q2 FY27 revenue of ₹291.4 crore and PAT of ₹18.3 crore. Order inflow was ₹1,491 crore; interim dividend of ₹1 declared.
- Order book
- ₹5,373 Cr
Indo Count Industries Results Update
Indo Count reported record Q2 FY27 income of ₹1,699 Cr and PAT of ₹132 Cr. H1 EBITDA grew 73% YoY to ₹420 Cr.